Acrivon Therapeutics, Inc. ACRV
2.10
(0.02)
(0.94%)
as of 25 Sep
- Market cap
- $90.9M
- P/E
- 0.0×
Follow ACRV
Insider Buys
alert about insiders buying in the last 12 month
| Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|
Current Ratio |
2.80 | 34.46 | 20.27 | 9.75 | 10.55 | 7.69 |
Net Debt/EBITDA |
0.50 | 6.17 | 3.87 | 1.82 | 1.95 | 1.43 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
0.53 | 0.86 | 0.97 | 0.71 | 0.82 | 0.82 |
Capex/Depreciation |
(1.15) | (6.43) | 6.49 | 0.46 | 1.00 | (1.82) |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| 0.00% | 100.82% | (42.50%) | (41.41%) | (54.07%) | (53.86%) | |
| 0.00% | (29.87%) | (21.66%) | (37.80%) | (48.11%) | (47.75%) | |
ROIC |
0.00% | 0.00% | (47.77%) | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(455.45%) | (16.61%) | (24.41%) | (50.38%) | (47.70%) | (71.04%) |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Free Cash Flow per Share |
(1.97) | (8.16) | (7.83) | (1.99) | (2.03) | (1.70) |
Cash per Share |
1.11 | 57.13 | 30.99 | 5.77 | 5.31 | 3.08 |
Shareholders Equity per Share |
0.88 | 56.62 | 41.36 | 5.49 | 5.23 | 2.92 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
0.88 | 56.62 | 41.36 | 5.49 | 5.23 | 2.92 |
Free Cash Flow |
(2.82) | (14.22) | (32.28) | (43.93) | (68.44) | (65.33) |
Working Capital |
1.11 | 97.49 | 125.58 | 116.39 | 164.42 | 104.78 |
Capital Expenditures |
(0.01) | (0.24) | (2.17) | (1.29) | (2.77) | (1.67) |
Net Current Asset Value |
0.79 | 92.53 | 121.34 | 112.62 | 161.83 | 103.24 |
| Other line items | ||||||
Quick Ratio |
2.58 | 34.18 | 19.61 | 9.58 | 10.43 | 7.57 |
Depreciation/Fixed assets |
0.22 | 0.13 | (0.16) | (0.80) | (0.62) | 0.19 |
Cash ROIC |
(100.88%) | (7.20%) | (10.80%) | (18.55%) | (19.69%) | (29.66%) |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
0.00 | 0.00 | 0.00 | — | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | — | — | — |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
(1.96) | (8.02) | (7.31) | (1.93) | (1.94) | (1.65) |
Capex per Share |
(0.01) | (0.14) | (0.53) | (0.06) | (0.08) | (0.04) |
Average Payables |
— | 0.55 | 0.93 | 2.98 | 2.90 | 1.52 |
Average Assets |
— | 54.39 | 143.91 | 159.75 | 167.43 | 163.15 |
Average Common Equity |
— | (16.11) | 73.33 | 145.84 | 148.99 | 144.65 |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates